Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial

BACKGROUND: Voriconazole has been recommended as primary treatment for patients with invasive aspergillosis. Intravenous and tablet formulations of posaconazole that have improved systemic absorption could be an effective alternative to voriconazole. We aimed to assess non-inferiority of posaconazol...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	LANCET 2021-02, Vol.397 (10273), p.499-509
Hauptverfasser:	Maertens, Johan A, Rahav, Galia, Lee, Dong-Gun, Ponce-de-Leon, Alfredo, Ramirez Sanchez, Isabel Cristina, Klimko, Nikolay, Sonet, Anne, Haider, Shariq, Diego Velez, Juan, Raad, Issam, Koh, Liang-Piu, Karthaus, Meinolf, Zhou, Jianying, Ben-Ami, Ronen, Motyl, Mary R, Han, Seongah, Grandhi, Anjana, Waskin, Hetty
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!